Good day, everyone, and welcome to the Tomi Environmental Solutions, Inc. First Quarter 2026 Financial Results Conference Call. At this time, all participants are placed on a listen-only mode. If you have any questions or comments during the presentation, you may press star 1 on your phone to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, John Nesbitt of IMS Investor Relations. Sir, the floor is yours.

Thank you for joining us today for the TOMI Environmental Solutions Investor Update Conference Call. On today's call is TOMI's Chief Executive Officer and Chairman, Dr. Halden Shane, EJ Shane, our Chief Operating Officer, and our Chief Financial Officer, David Vanston. A telephone replay of today's call will be available through May 15th, the details of which are included in the company's press release. A webcast replay will also be available on Tomey's website, www.steramist.com. Certain written and oral statements made by management of Tomey may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements should be evaluated in light of important risk factors that could cause actual results to differ materially from our anticipated results. The information provided in this conference call is based upon the facts and circumstances known at this time. Please refer to our filings with the Securities and Exchange Commission for discussion of these risk factors. The company undertakes no obligation to update these forward-looking statements after the date of this call. I will now turn the call over to Tomy's Chief Executive Officer and Chairman of the Board, Dr. Alden Shane. Please go ahead.

Thank you, John, and thank you all for joining us today. Q1, 2026 marked a healthy start to the year, highlighted by a pivotal strategic development for Tomy. Our first quarter results demonstrated significant momentum across key metrics. Revenue increased by 5% year-over-year and 67% sequentially from Q4 of 2025. Notably, applicator sales in Q1 alone surpassed our total applicator sales for the entire year of 2025, representing a remarkable 139% year-over-year growth. This success underscores the effectiveness of our Razer-Razer Blade consumable model as we expand our installed base. Additionally, BitSolution sales have consistently grown by 21% annually since 2024 and remained above the 2025 levels in Q1 of 2026. We also achieved a 15% reduction in operating expenses compared to Q1 of 2025 while maintaining our full capacity. The company also generated positive operating cash flow of $296,000, which is a $572,000 improvement over the same period last year. A notable trend this year is strengthening and dynamic nature of our integrated project pipeline, which continues to demonstrate meaningful momentum. This is the pipeline the company has highlighted since November of 2025 and which evolves as we advance or complete contracts. The expansion of this pipeline aligns closely with growth in our backlog. And we are disclosing only opportunities that suppliers have indicated are near signing. These opportunities tend to involve longer sales cycles, while near-term closings are communicated as they firm up. They do not represent our entire potential opportunity. The trend is reflected in our backlog of orders. At year end of 2025, Tomi reported 1.6 million in backlog, which grew by half a million by the close of Q1, 2026, and is currently at 2.2 million. This steady backlog expansion underscores the strength of our automated integrated system and the many service offerings we implemented. Critically, backlog growth continues even as we fulfill existing orders, illustrating demand and execution across sales. At the end of quarter one, Tomey received 440,000 annual purchase orders for recurring decontamination services with a leading global medical technology company. This contract involves quarterly professional IHP decontamination services for critical cleanroom and laboratory environments, aligning perfectly with our strategy to build a high margin, repeatable revenue model, in addition to increasing the backlog order number. In Q1, we achieved several other notable milestones. A private East Coast research university purchased and installed a Sturimus hybrid system for high-level decontamination of reusable medical equipment. We also sold a custom-engineered system in the UK to an international pharmaceutical manufacturer, which was integrated into Total Clean Air's module cleanroom platform. And we established Total Clean Air as our preferred European partner for Stereomist IHP technology when the UK Health and Safety Executive granted regulatory authorization for a bit solution and Stereomist IHP products. The food safety sector is gaining real traction. We launched an important case study that demonstrated up to 95% reduction in sanitization testing costs for an egg food manufacturer. Our long-standing partner, Disinfect Care, secured a service contract at a major Mexican dairy facility where rigorous testing highlighted SturryMist IHP's efficacy while preserving product quality. Further, the end user is looking to expand its use of SturryMist IHP in Mexico to its other facilities. There are other positive food safety tests that the company has received to be discussed at a later date. This is all exciting stuff for us. Regulatory advancements have also played a critical role in our progress. In February, we received official authorization from the UK Health and Safety Executive for our BIT solution and SteriMist IHP products for use in Great Britain and Northern Ireland. In March, we secured product authorization from the Dutch Regulatory Authority, making our first product approval within an EU member state and facilitating a streamlined recognition pathway across the EU. And this past week, we received notification of further approvals in Germany, Belgium, Denmark, and Hungary. We anticipate many other regulatory wins in the near future. On April 30, 2026, we executed a non-binding letter of intent to merge with Carbonium Core Incorporated, a U.S.-based producer of nuclear-grade graphite for advanced reactor technologies and AI data center infrastructure. Carbonian Core boosts a vertical integrated production platform and exclusive purification technology developed with Oak Ridge National Laboratory. This merger targets a specialty market currently dominated by foreign supply, coinciding with increasing domestic demand for non-Chinese origin graphite due to new U.S. FEOC regulations and federal support for advanced nuclear energy. To be clear, with this transaction, our country will become the leader in Generation 4 nuclear reactors, a class of advanced nuclear systems designed to offer significantly improved safety, efficacy, and sustainability compared to current commercial plants. These reactors are characterized by their ability to operate at a much higher temperature gas-cooled reactor pebble bed module, recognized as the world's first operational generation 4 reactor. These systems aim to overcome limitations of current technology by producing more fuel than they consume and ensuring that severe accidents resulting in radioactive release are physically impossible. Under the terms of the LOI, Corbonine Core would become a wholly owned subsidiary of Tomey. Former stockholders would receive Tomey common stock equal to 19.99% of shares outstanding prior to the merger, along with shares of a newly created series of convertible preferred stock, implying an enterprise valuation of $120 million. We aim to finalize definitive agreements by May 30, 2026, with a 45-day exclusivity period in place. The strategic rationale for this transaction is compelling. It aims to diversify Tomy's business by merging a domestic platform focused on advanced nuclear-grade graphite, graphene, and lithium materials with our existing Sturimus decontamination business. This integration has the potential to unlock significant long-term value for our shareholders while enhancing and expanding the Sturimus brand. Please note that the LOI is non-binding and the completion of the transaction is subject to definitive agreement, due diligence, and customary closing conditions, including stockholder approval. I'll now turn the call over to our Chief Financial Officer, David Vansman, for a review of our Q1 financial results.

Thank you, Dr. Shane. Our complete financial statements are in our Form 10Q filed with the SEC and in today's press release. I will walk you through the key metrics for the three months ended March 31, 2026, compared to the same period in 2025. Revenue for Q1-26 was $1.6 million, a 5% increase from $1.5 in Q2-25 and a 67% sequential increase over Q4-25. Product revenue increased $300,000 or 31%, driven by higher equipment and CES-related sales. Service revenue decreased by 234,000, or 41%, reflecting the timing of decontamination project completions and service engagements in the period, which management views as temporary. Gross profit was 832,000, or approximately 50% of revenue, compared to 952,000, or approximately 6% of revenue in Q1-25. The decrease in profit margins reflects strategic price discounts to drive equipment adoption and an unfavorable product mix shift towards lower-margined equipment sales. Management views these factors as temporary, as growth in high-recurring margin BT solution consumers and applicant sales is expected to support margin recovery in future periods. Total operating expenses were $1.48 million, a reduction of $248,000, or 15%, compared to $1.7 million in Q1 2025, reflecting lower general and administrative selling, professional, and consulting costs across the board. The loss from operations was $626,000, an improvement of $128,000 compared to a loss of $754,000 in Q125. The net loss was $811,000, or $0.04 a share, per basic and diluted, compared to a net loss of $256,000, or $0.01 per share, in Q125. It is important to note that Q125 net loss included a non-recurring employee retention credit of $535,000 and related interest of $83,000. Excluding these one-time items, Q125 adjusted net loss would have been approximately 874%, making Q21 a meaningful year-over-year operating improvement. Cash flows. Our net cash provided by operating activities was $296,000 for Q126, an improvement of $572,000 from the $276,000 used in Q125, primarily driven by improved working capital management and growth in deferred revenue from customer deposits. Net cash used in investing activities was $5,000. The net cash in financing activities was $98,000, reflecting $192,000 in repayments on the agile capital sale of future receipts agreement, partially offset by $94,000 in net ELOC proceeds. We ended the Q1 with cash of $280,000 and working capital of approximately $394,000, compared to a cash of $88,000 and working capital of $1 million at year-end 25. The $630,000 decline in working capital reflects the net loss incurred during the period. Accounts receivable increased by $73,000 on higher revenue, and infantries remained relatively flat. On the liability side, are accounts payable in accrued expenses increased by $993,000 and deferred revenue increased by $177,000. Reflecting our deposit policy on customer orders, our accumulated deficit as of March 31st, 2026 is $58.9 million. During Q1, we raised $149,000 in gross proceeds through the issuance of 336,147 shares of common stock under our $20 million equity line of credit. I encourage investors to review our form 10Q in full, including the risk factors and notes to financial statements. I will now turn the call over to our Chief Operating Officer, E.J. Shane, for an update on what we expect in the next upcoming months and the rest of the year.

Thank you, David, and good afternoon, everyone. As Dr. Shane referenced, applicator sales increased at 139% year over year. This is a strong signal that customers are expanding their deployment of our patented cold plasma technology. The applicator is a critical component that enables our IHP to be used more broadly. This growth is a game changer. It shows customers are increasing their utilization of our tech. Customers who already own mobile fogging systems are expanding their use of IHP across additional areas within their facilities by acquiring more applicators, permanent or semi-permanent, driving higher sales of BitSolution, our consumable The Ceramis Integrated System Platform, or SIS, hybrid, and our original custom-engineered system, or CES, are essential to our integration pipeline. Collectively, it is these offerings that are expected to significantly boost BitSolution revenues. Our current immediate integration sales and pipeline is currently at $4 million across 14 customers and seven separate orders received with the remaining projects awaiting capital approval. This is an update that reflects changes since our last call. Some customers have been removed due to completed sales in quarter one, while three new customers have been added and two additional contracts have been secured. The seven orders mentioned are all in various stages of manufacturing and delivery, which will impact revenue timelines. The full company sales pipeline opportunities for all our offerings, from mobile off-the-shelf capital equipment, automated integrated custom designs, and IHP corporate service deployment, is projected to be between $22 million and $33 million. This is the complete opportunity list. It includes interested parties who have received quotes or planned implementation and or installations of IHP technology across all our industries. Dates are not yet set, but these are parties who have expressed strong interest in Staramis IHP. Of this list, $9 million is categorized as active, approved, or anticipated for purchase this year based on customer requests or the progression of the sales process. $4 million is allocated to automated integration orders, and an additional $5 million is attributed to mobile off-the-shelf capital equipment, support service contracts, and IHP corporate deployment. Based on the latest reports and trends that I just referenced, Tomei generated approximately $1.7 million in revenue in quarter one, currently holds a backlog of $2.2 million. This includes only some of our integration automation pipeline, which stands at a total of $4 million, with a potential $5 million in mobile equipment sales. Conservatively, we anticipate $2 million in consumables and other smaller revenue streams. Taken together, this yields a credible path for Tomi to achieve its projected 2026 revenue target. Our strong base of high-quality, large customer base has been the key driver for these trends. These customers have helped in this potential growth through referrals, relocating projects, in expanding Staramus IHP adoption at their new facilities, as well as expanding usage after initial purchases. A concrete example is Merck. Currently has approximately 1.2 million in open estimates across five different locations. While Merck is not included in the near-term numbers I cited earlier due to their longer decision cycles, they remain an active partner and are captured in the full opportunity pipeline. Additionally, one of our first large pharmaceutical clients is approaching a decision on their CES proposal, which could represent the largest such installation to date and an uplift of future revenues for TOMI. On January 6th, we announced that a private East Coast research university purchased and installed a Staramis hybrid system. In this past week, we just received notification that we won a second award with them. And for my last example, a third site in Berlin, Germany, is set to begin trials in June for an iHealth customer that we onboarded in quarter one of last year. This customer is also utilizing an open monthly bit solution order, aligning perfectly with our business model. Furthermore, none of this reflects opportunities tied to additional regulatory requirements. Our efforts regarding the food contact notification with the United States Food and Drug Administration, NSF Standards Department for Biological Safety Cabinets, the FDA 510K for medical devices, and further European Union registrations, all of which hold substantial potential based on the current market demands. On May 1st, we officially opened a task group with NSF, cleaning and sterilizing the biological safety cabinet sector. We want to be added to their informational Annex G so that our partners are deploying Steremis IHP to outperform legacy decontamination methods, including spore cleanse, formaldehyde, and BHP. Ultimately, our goal is to enable these service providers worldwide to compete effectively by incorporating IHP into their offerings for BSCs, which allows them to complete more treatments in a single day compared to the older technologies referenced. The food safety sector remains promising, but progress will depend on ongoing regulatory developments. For example, Nestle's planned expansion is contingent on obtaining additional international registrations beyond the European Union and on updating EU registration requirements to include an alternate class. We are engaging with three large customers who have expressed strong interest in our SCM for baby formula to deploy IHP technology. In parallel, we are conducting internal testing on dried ingredients for a current customer who already owns their handheld devices and exploring a scaled deployment. This testing phase aims to validate performance and readiness for a broader rollout. Last month, we attended Interfex in New York City, one of the premier trade shows in the pharmaceutical biotechnology and medical device industries. And at the show, we finalized the sale with a prominent American healthcare company, renowned for its innovative medications and pre-mixed, ready-to-use formulations. In summary, we maintain that with a broader and more diverse range of Staramis delivery systems, this growing integration pipeline, expanded support services designed to accelerate IHP qualification and ongoing referrals and expansions from our existing customer base, that Tomi is well-positioned to shift revenue mix positively and enhance profitability. I thank you all for your time and attention, and I hope this provides a clear sense of the progress and initiatives that we are pursuing. I will now turn the call back to our CEO, Dr. Halden-Shane.

Thank you, E.J. So as a special note, I want to talk about the United States of America is very hungry for rare earth minerals and materials that are mined and or synthetically produced in America. The synthetic production of nuclear-grade graphite and the convergence of these technologies, whether it be nuclear-grade graphite, graphene, or lithium, present a transformative opportunity to address critical global challenges. TOMI's future is an advancement of autogenous systems, AI-powered robotics. Quote, our Sterabot, registered, of course, and specialized disinfection drone technology manufactured with lightweight, strong graphene shells and plenty of battery power will enable proactive solutions for ecological stability, logistics efficacy, and public safety. Of a special concern of mine is the honeybee industry. It is in dire straits. The association is seeing a lot of viral losses now, not just from the formed wing virus or DWV, but real losses in bees because of what the industry refers to as deadouts, where the comb gets a virus and kills all the bees. Since 2007, there has been an 80% decline in bee populations. It can be devastating because it's not just concerning the DWV virus and its variants, but additional viruses such as chronic bee paralysis and Israeli acute paralysis. The IHP micro-miss can reach the entirety of the comb, including the nooks and crannies, without leaving any damage to the wax. Currently, the only available product on the market to alleviate these viruses is very expensive gamma irradiation process. The combs are very expensive, thus beekeepers don't want to dispose of the comb near use gamma irradiation. An IHP disinfectant drone would certainly help save the pollinators of the world and ultimately the world. This is what we do, innovating for a safer world. Thank you all and thank my small team for all the great work that they do. So looking ahead, Tomi enters Q2 of 2026 with strong commercial momentum and expanding recurring revenue base and a transformative strategic transaction underway. Our focus strategy for the balance of the second quarter is to advance the Carbonian core transaction towards definitive agreement and closing, drive recurring revenue growth through increased bit solution sales, open order policies, and expanded IHP corporation service contracts, and strengthen balance sheet flexibility through our ELOC and additional financing initiatives. With that, operator, please open the call to any questions.

Everyone at this time will be conducting a question-and-answer session. If you have any questions or comments, please press star 1 on your phone at this time. We do ask that while posing your question, please pick up your handset if you're listening on speakerphone to provide optimum sound quality. And once again, if you have any questions or comments, please press star 1 on your phone. Your first question is coming from Amit Dail from HC Wainwright. Your line is live.

Thank you. Good afternoon, everyone, and great to see all the developments underway at the company. My first question was on the gross margin side. It was a little bit softer, I guess, because of some discounts on offerings. Just wanted to see how this will bounce back, and would you potentially need to continue providing those discounts at least for the hardware side of things you know to get initial orders with customers going no I know they will bounce back and we don't plan on providing these types of discounts again okay understood and then you know the pipeline looks pretty robust at least 4 million in sort of you know certain orders it looks like sequentially do you think we should expect revenues to grow from here through 2026 or should we expect some lumpiness in our revenues are recognized no most definitely we should see growth through 2026 and into 27 and beyond okay any any traction from these you know recent news flow around hantavirus etc um has there been any follow-up with companies or customers from those developments for you guys not at the moment but you know as you know i mean this hantavirus is it's not close to us as where the ship is located um the interesting part about this

is that they've let a lot of people off the ship, and there's usually like an eight-week period before you test positive for this. So we're prepared and ready to help and assist in any way.

But at the moment, we haven't heard from anyone, and we can't get our equipment into the area quick enough to help the ship because first of all I mean all the all the passengers most of them have been disembarked okay understood this last one for me on this transaction with carbonium you know how is the diligence going so far and you know do we have the expertise to sort of you know properly investigate the technology these folks are offering and then just a follow-up on that one is you know, will this be sort of a development stage, you know, entity you are, you know, acquiring and how much more investments do you think it would need if you were to close the deal to progress that company to commercialization?

Well, there's a lot of questions. Yes, it's in its early stages. We are forming a committee in the early part of next week to help with the due diligence. and again you know we're aiming towards getting a definitive agreement and doing our due diligence we're aware of the technology and its ability and you know with Oak Ridge and some I don't want to get too ahead of Carbonian in releasing certain things but we're pretty secure that this will go forward. And as far as investments, that's something that needs to be determined. We haven't quite yet come out with any numbers like that. And you can understand this is just the very early stages of this potential merger.

Okay, Doug, that's all I have. Thank you so much.

Thank you. Thank you. Your next question is coming from Todd Felt from Stonex Wealth Management. Your line is live.

Hey, Doc and EJ. Congratulations on a good quarter and on the Carboni merger. I know I'm excited to see how that progresses. I did have two questions on it. The first is, after the merger is approved and closed, I know there's a 19.9% shares of common stock that are going to them in addition to the convertible preferred. If all that convertible preferred was converted to common at $1, what would be the total shares outstanding?

It's a good question. Probably somewhere in the neighborhood of $32 million, maybe $31 million. We haven't really done the exact performa on that yet, but I would have to say that would be the amount.

Okay. And then second of all, I listened to a television interview that you had done with Sindor, the head of Carbonium, and he was projecting revenues in 2028 of $1.4 to $1.5 billion. Is that correct, or did I hear that wrong?

No, you heard that correct. This is a huge industry, and they have the ability to capture it from the synthetic, you know, nucleo-graphite end. And, you know, again, I don't want to get ahead of the curve with him, but, you know, what he said is $1.4, $1.5 billion.

Okay, and finally, outside of getting shareholder approval, are there any other major obstacles, assuming that your committee checks out on all the due diligence, are there any other major obstacles on getting this to the closing line?

There shouldn't be Again, it's a deal It's early and you never know What obstacles get thrown at you But we're hoping There aren't and we're able to Complete this in a relatively Timely manner Okay, thanks for the questions, I appreciate it Thank you Todd I'm really excited about it, thank you Thank you so much Thank you, and once again everyone If you have any questions or comments Please press star then 1 on your phone.

Please hold while we pull for questions. Your next question is coming from John Nelson. Your line is live.

Hi, congrats on the quarter and progress being made on the Tomy business and also the potential from the carbonium merger for the combined company.

Thank you, John.

First question is, I saw the slideshow from your 8K on carbonium core, and they're projecting profitability, I believe, next year, according to the slides. Am I correct on that?

That's what I understand.

Yeah, which would be phenomenal for them to get out of the gate this fast and be profitable almost immediately. So anyway, thanks for confirming that. The other thing in the slides was an independent valuation. Do you know who did that independent evaluation of Carbonium Core?

It was done by a professional evaluation service. I don't know if I can – I'd rather not publicly say until they approve it, But, you know, it was a very large 47-page evaluation, and it covered everything that we would want to see in it, you know.

So going forward, I think they'll be – Yeah, do you think that they can – if you complete the merger, do you think they can release that or you can release that as a shareholder?

Yeah, I would think we would be able to once this happens.

Excellent. Thank you. The other questions relate to the Tomy business. On the honeybee industry, you talked extensively about the concerns and how styromist can remedy a significant amount of problems that the bee industry is facing. How do you plan to go after that market?

Well, currently, I think I've mentioned this on prior calls. I have been trying to contact the association. I end up joining the association, and I follow everything that goes on in it. Recently, our marketing department reached out to an administrator, and they would like to do a study. So now I'm really excited that we got their attention and hopefully they'll be able to do this study fairly quickly. You know, I know the industry is in dire straits to eliminate, you know, the effects of all these viruses which are, you know, going ahead and causing death to the bees, which, you know, I mean, I don't think we want our kids to grow up in a world that doesn't have pollinators.

Yeah, we definitely need it. So I was curious as to how quickly a study might be able to be accomplished, And I would think that the beehive people would be extremely happy to get something that would help preserve their hives.

Yeah, I mean, I think, you know, the real answer, you know, that they've been going with, you know, in the past is very expensive. And I think gamma irradiation, you know, it gives you a new hive, I guess, but most beekeepers don't have that type of money where our solution would be fairly inexpensive for them to eliminate the mites, the viruses in the cone and to go ahead and protect it going forward. So that would be great to have this technology, which was innovative from the beginning, to be able to protect the honeybee population around the world.

Definitely. Definitely. Then, do you have any specific goals as to timing to reach either profitability or positive cash flow over the next quarters or a year? year?

Yeah, I think within this year we'll be profitable.

Okay, good. And then you mentioned in a previous press release the going after the robo-taxi market and do you see that as being addressed by a just the Steremist handheld units or do you think that there might be a possibility of actually kind of installing a fixed unit within the cab that could dispense Steremist on a regular basis after every ride for example yeah I think the, you know, I think it's too early.

What our plan is initially is to mold our backpack using existing human humanoid type robotics. And we, we know we can handle the software adaptation of it and go ahead and put our, our applicator in the left hand, replace the hand and put the applicator in there or trigger the hand to push the applicator and have the right hand to move objects or to move doors or open things and things like that. So I think that's going to be the fastest to market. There are a lot of companies, not just Tesla and not just Waymo, But there are five or six companies worldwide that are starting to put out robo-taxis. And as the world evolves, this autonomous vehicle seems like something that's going to be around forever. So they do have to clean them, and our technology would be the fastest and quickest way to get that done. As far as an installation, I don't know if the cost is going to be practical for them. It certainly would work for us, and they would need some time between each ride to disinfect or decontaminate the space, and I don't know if their model is set up to wait because I'm in West Hollywood, L.A. area, and I use Waymo a lot, and they're always running two or three minutes late because they're dropping someone off. So it's possible that they could, maybe if we could get the time down to, let's say, three minutes or five minutes, that they could sterilize them between the routes. I mean, anything's possible today. Okay.

And with regards to use of Stiramis in closed spaces, it would seem like Stiramis would be perfect for decontamination of airlines and cruise ships and even military vessels because of the risk of contamination infection. Is it just that that market takes – what kind of explanation do you have for the timelines of penetrating those kinds of enormous markets?

So I think, you know, we'd have to be a much bigger company and to get grant writers to write grants for the markets, especially now they're building ships, you know, under the current administration. And it would be an ideal time to start implementing the technology or putting it into ships. I'm not sure what the stress test would be to see what stays in place, you know, in rough waters, you know, versus smooth waters and things like that. So, I mean, it's all possible. And, you know, I foresee in the future this happening. Same way with aircraft. What I'm really more excited about is unmanned aircraft, as we all know. And we see in the military budget, there's $70 billion being put aside for drones. When the technology started, when I bought it from the defense contractor and the initial DARPA project, it was for the use of unmanned planes that were returned to earth or returned to ground or returned to ship. And that's what it was used for. So with the drone market blowing up like it has all over the world, this is the product to be used for the disinfection decontamination of unmanned aircraft around the world.

Are you working with any particular companies, even if you can't name them at this time, regarding the use of steroids?

Not at this time that I'm aware of, and I don't know if we can sit. E.J., do you have a more unclassified answer to that?

Not at this time, Dr. Shane. Sorry, John.

Okay. I'll keep you updated. Thank you. Appreciate it. Of course. And let's see. Is there anything else that has changed as far as the applicators or the equipment used in Ceramist or any new ways to use Ceramist, either in the commercial or retail-type settings? Yes.

I'll let EJ answer it. I just tried it on my dog, and he stopped barking, so that was positive. EJ?

Yeah, no. There's not been any changes to the applicators itself. We just changed the way in terms of how we sold it with the integration projects and the standalone system. So there's multiple different versions of the applicators that we can now offer, regardless of the industry you're referring to. So that's been helpful, yeah.

Okay. You know I was kidding, John. Yes. That was a good one. Thank you.

I don't want to get a letter from Tita. Thank you, John.

Thank you.

Thank you. We've reached our allotted time for Q&A. I'll now hand the conference back to management for closing remarks.

Well, I just want to thank everybody for joining and for continuing the voyage with us and this amazing product and this amazing world. Have a great day, wherever you might be.

Thank you. Everyone, this concludes today's event. You may disconnect at this time and have a wonderful day. Thank you for your participation.